NEW YORK (GenomeWeb News) – Qiagen said after the close of the market Thursday that it has acquired AmniSure International, a privately held point-of-care diagnostics firm, for an undisclosed amount.

Boston-based AmniSure sells an assay for determining whether a pregnant woman is suffering rupture of fetal membranes. Qiagen said as many as 30 percent of pregnant women are checked for this condition in clinical settings.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Genome Research this week: multiplex genotyping of germline and somatic short tandem repeats, graph-based regularization, and more.

A lack of funding may lead more than two dozen research facilities in Australia to shut down in three months.

Researchers report that paternally inherited genes are more likely to be expressed in mice.

In PNAS this week: Akt3 amplification in glioma progression, Tibetan Plateau frog genome, and more.